Clopidogrel in secondary ischemic stroke prevention

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 2, 2008, Pages 119-125

  Belvís, Robert ^a   Pagonabarraga, Javier ^a   Santamaría, Amparo ^a   Kulisevsky, Jaime ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

AMI (acute myocardial infarct); ARR (absolute risk reduction); ASA (acetylsalicylic acid); IS (ischemic stroke); PAD (peripheral arterial disease); RRR (relative risk reduction); TIA (transient ischemic attack)

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN; TELMISARTAN; TICLOPIDINE; WARFARIN; DRUG DERIVATIVE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTERY DISEASE; BLEEDING; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INDIGESTION; INTERMITTENT CLAUDICATION; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VOMITING; BRAIN ISCHEMIA; DRUG COMBINATION; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; PATHOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ASPIRIN; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TICLOPIDINE; TREATMENT OUTCOME;

EID: 51149091908     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008784705340     Document Type: Review

References (65)

1. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: Definition for use in multicenter clinical trial. Stroke 1993; 24: 35-41.
2. Grau AJ, Weimar Ch, Buggle F, et al. Risk factors outcome and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke 2001; 32: 2559-2566.
3. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 80-106.
4. Antithrombotic Trialist Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. Alvarez-Sabin J, Montaner-Villalonga J. Antiagregación plaquetaria en la prevención secundaria del ictus después del ESPS-2 y del CAPRIE. Rev Neurol 1999; 29: 780-784.
6. Gent M, Blakely JA, Easton JD, et al. Turpie AGG for the Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
7. Has WK, Easton DJ, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507
8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
9. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006; 367: 1665-1673.
10. Jarvis B, Simpson K. Clopidogrel. Drugs 2000; 60: 347-380.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
12. Ringleb PA, Hacke W, Hirsch AT, et al. The benefit of clopidogrel over aspirin is amplified in high-risk subgroups with a prior history of ischemic events. Eur Heart J 1999; 20: 666.
13. Rupprecht HJ. Consistency of the benefit of clopidogrel across a range of vascular related endpoints: Results from CAPRIE. Eur Heart J 1998; 19: 52.
14. Bhatt DL, Topol EJ, Hacke W, Hirsh AT. Remarkable consistency of benefit of ADP receptor blockade compared with aspirin across a variety of endpoint, including avoidance of rehospitalization. Eur Heart J 1999; 20: 377.
15. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE. CAPRIE steering committee and investigators. Clopidogrel versus aspirin in patients at risk of ischemic events. Drug Safety 1999; 21: 325-335.
16. Lok DJA. Comparative gastrointestinal tolerability of clopidogrel and aspirin. Results from the CAPRIE trial. Eur Heart J 1998; 19: 52.
17. Bogousslavsky J. Gastrointestinal bleeding with clopidogrel compared with aspirin. Cerebrovasc Dis 1998; 8: 43.
18. Fork F-T, Lafolie P, Tóth E, Lindgärde F. Gastroduadenal tolerance of clopidogrel 75 mg versus aspirin 325 mg in healthy volunteers: A gastroscopic study. Scand J Gastroenterol 2000; 35: 464-469.
19. Morais J. Use of concomitant medications in the CAPRIE trial: Clopidogrel is unlikely to be associated with clinically significant drug interactions. Eur Heart J 1998; 19: 15.
20. Havranek E, Weinberger J. Concomitant use of ACE inhibitors and antiplatelet therapies: Clopidogrel versus aspirin. J Hypertens 1999; 17: 57.
21. Lau W, Waskell L, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new frug-drug interaction. Circulation 2003; 107: 32-37.
22. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopiryridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779-1784.
23. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-628.
24. Blecic S. Atherothrombotic events often indicate disseminated atherosclerosis: Data from CAPRIE. Cerebrovasc Dis 1998; 8: 34.
25. Hacke W, Hirsch AT, Topol EJ. The benefit of clopidogrel over aspirin is amplified in high-risk subgroups with a prior history of ischaemic events. Eur Heart J 1999; 20: 666.
26. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with history of diabetes mellitus. J Am Col Cardiol 2000; 35: 409.
27. Bhatt DI, Hirsch AT, Rinbleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel compared with aspirin. Am Heart J 2000; 140: 67-73.
28. Bhatt DL, Foody J, Hirsch AT, Ringleb P, Hacke W, Topol EJ. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol 2000; 35: 326.
29. Cannon CHP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with asymptomatic atherothrombosis (CAPRIE Trial). Am J Cardiol 2002; 90: 760-762.
30. Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: The example of clopidogrel therapy for the prevention of vascular events. Am J Med 1999; 107: 568-572.
31. Albers G, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients? Stroke 2001; 32: 2948-2949.
32. Alberts MJ, Easton JD. Clopidogrel plus aspirin for stroke prevention. Stroke 2002; 33: 2546-2547.
33. Herbert JM, Bernat A, Falotico R, Lale A, Savi P. The anti-aggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512-518.
34. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 98: 2461-2469.
35. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin, and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.
36. Moshfegh K, Redondo M, Julmy F, et al. Comparison of antiplatelet effects of clopidogrel, aspirin and their combination in patients following myocardial infarction. J Am Coll Cardiol 2000; 391: Abstract 1151-98.
37. Bhatt D, Bertrand M, Berger P, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.
38. Bajzer CT, Kapadia SR, Yadav JS. Clopidogrel use in carotid artery stenting. Am J Cardiol 1999; 84: 7.
39. Moussa I, New G, Lawrence E, et al. Clopidogrel may enhance the clinical efficacy of carotid artery stent implantation: The EMILY registry. Stroke 2000; 31: 299.
40. Nutescu E, Helgason CM. Combination aspirin-clopidogrel therapy in patients with ischemic stroke. Stroke 2000; 31: 298.
41. Diener HC, Bogousslavsky J, Brass LM, et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc Dis 2004; 17: 253-261.
42. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
43. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233-2240.
44. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
45. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969
46. Serebruany VL, Malinin AI, Ziai W, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke 2005; 36: 2289-2292.
47. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomized controlled trial. Lancet 2006; 367: 1903-1912.
48. Gorelik PhB, Hanley F. Clopidogrel and its use in stroke patients. Stroke 1998; 29: 1737.
49. Sarasin FP, Gaspoz JM, Bounamuaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000; 160: 2773-2778.
50. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis. Clin Ther 2000; 22: 362-370.
51. Warlow Ch. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002; 33: 2137-2138.
52. Diener HCh. Aspirin therapy should be first-line treatment in secondary prevention of stroke - against. Stroke 2002; 33: 2138-2139.
53. Donnan G, Davis SM. Aspirin therapy should be first line. Probably, but watch this space. Stroke 2002; 33: 2139-2140.
54. Benavente O, Hart R, Palacio S, et al. Secondary Prevention of Small Subcortical Strokes (SPS3). Stroke 2003; 34: 238.
55. Darius H, Rupprecht HJ, Kress P, et al. Accelerated inhibition of platelet activity by clopidogrel loading dose in patients following coronary stent implantation. Thromb Haemost 1999; 82: 264.
56. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 2005; 111: 2099-2106.
57. Yao SK, McNatt J, Anderson HV, et al. Concomitant administration of clopidogrel with tissue-type plasminogen activator delays reocclusion in canine coronary arteries. Circulation 1990; 82(s3): 770.
58. Hoffman P, Pottier P, Sainte Marie M, et al. Clopidogrel enhancement of rt-PA thrombolysis in a thromboembolic model of cerebral ischemia in rats. Fibrinol Proteol 1998; 12: 97-105.
59. Bassand JP, Cariou R, Grollier G, et al. Clopidogrel-rt-PA heparin combination in the treatment of acute myocardial infarction. Semin Thromb Hemost 1999; 25 (s2): 69-75.
60. McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis 2007; 24: 85-91.
61. Halfon, S., Somers, N., Yamin, R., First, S.: WO070912353 (2007).
62. Klaus, S.J., Langsetma, P.I., Jacob, C.T.: WO07097929 (2007).
63. Liversidge, G.G., Jenkins, S.: WO07086014 (2007).
64. Brendt, J.T., Serebruany, V.L., Winters, K.J.: WO07024472 (2007).
65. Shi, X., Bousser, M.G., Picard, D.: WO07106049 (2007).